OSCR
Oscar Health, Inc.
OSCR has the edge over QGEN overall, supported by stronger fundamentals and stronger modeled upside.
QGEN
Qiagen N.V.
QGEN has lower modeled downside risk, despite its lower overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
QGEN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Healthy |
QGEN's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over QGEN in the historical PE scenario, which offers more potential upside but is not a forecast.
QGEN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 20x | $50.10 | — |
| Cheap | 21x | $41.00 | -18% |
| Fair | 26x | $51.64 | +3.1% |
| Current | 26x | $50.10 | — |
| Expensive | 99x | $194 | +287% |
Historical ranges are pointers, not guarantees.
QGEN's PE is in its fair range at 26x. If earnings grow as analysts expect, today's price would be 20x next year's earnings, in its cheap range.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over QGEN on the outlook, with more favorable profitability expectations.
QGEN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for QGEN, with profitability holding steady.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
QGEN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.54 | +30% |
| Q2 2026 | $1.95 | +15% |
| Q1 2026 | $1.89 | +340% |
| Q4 2025 | $1.97 | +418% |
| Q3 2025 | $1.86 | +354% |
| Q2 2025 | $1.70 | +431% |
| Q1 2025 | $0.43 | -72% |
| Q4 2024 | $0.38 | -75% |
| Q3 2024 | $0.41 | -72% |
QGEN has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over QGEN on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
QGEN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $535M | +0.3% |
| Q1 2026 | $492.3M | +1.8% |
| Q4 2025 | $540.4M | +3.7% |
| Q3 2025 | $532.6M | +6.1% |
| Q2 2025 | $533.5M | +7.5% |
| Q1 2025 | $483.5M | +5.4% |
| Q4 2024 | $521.2M | +2.4% |
| Q3 2024 | $501.9M | +5.5% |
QGEN's revenue has grown year over year for nine quarters in a row: $535M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 25% | +1.9 points |
| Q1 2026 | 24% | -0.2 points |
| Q4 2025 | 28% | +5.6 points |
| Q3 2025 | 24% | +1.9 points |
| Q2 2025 | 23% | +69 points |
| Q1 2025 | 24% | +3.2 points |
| Q4 2024 | 23% | +1.1 points |
| Q3 2024 | 22% | +1.9 points |
QGEN has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over QGEN on cash flow, with more consistent year-over-year improvement.
QGEN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $157.8M | +31% |
| Q1 2026 | $53.7M | -44% |
| Q4 2025 | $117.2M | -17% |
| Q3 2025 | $119M | -14% |
| Q2 2025 | $120.6M | -5.6% |
| Q1 2025 | $95.8M | +1.2% |
| Q4 2024 | $141.9M | +43% |
| Q3 2024 | $138M | +65% |
QGEN generated $448M in free cash flow over the past year, down 9.8% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
QGEN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.5% | -1.1M shares |
| 1 year | -4.7% | -10.4M shares |
| 3 years | -7.1% | -15.8M shares |
| 5 years | -10% | -24.1M shares |
| Available history | -8.3% | -18.7M shares |
QGEN has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | $496.7M |
| Q4 2025 | $2.7M |
| Q3 2025 | $9.3M |
| Q2 2025 | $10.3M |
| Q1 2025 | $280.1M |
| Q4 2024 | $906,000 |
| Q3 2024 | $6.2M |
QGEN spent $509M buying back its own shares over the past year, up 71% from the year before.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over QGEN on leverage, with a lower net debt burden relative to earnings.
QGEN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 1.2x | Healthy |
| Q1 2026 | 1.4x | Healthy |
| Q4 2025 | 1.1x | Healthy |
| Q3 2025 | 1.1x | Healthy |
| Q2 2025 | 1.0x | Very low |
| Q1 2025 | 2.1x | Moderate |
| Q4 2024 | 2.6x | Moderate |
| Q3 2024 | 2.6x | Moderate |
QGEN's net debt is about 1.2 years of its operating earnings (EBITDA), up from a year a year ago.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
QGEN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 71.4 | Overbought |
| Stochastic | 92.8 | Overbought |
QGEN's weekly RSI is 71 (overbought) and its Stochastic is 93 (overbought).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over QGEN on valuation relative to its sector.
QGEN PE vs Healthcare Sector
| Metric | QGEN | Sector median | Relative |
|---|---|---|---|
| PE | 26x | 26x | 0.6% below |
| PE % | 44 | 29 | 15 pts above |
QGEN is trading at 26x earnings, in line with the Healthcare sector's median of 26x.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
QGEN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $47.7 | 5.1% above |
| 20 week MA | $44.4 | 13% above |
| 50 week MA | $43.5 | 15% above |
| 100 week MA | $44.1 | 14% above |
| 200 week MA | $43.9 | 14% above |
QGEN is in an uptrend: it's above all five of its weekly moving averages, and 14% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over QGEN on returns for 2026, with the stronger performance.
QGEN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $33.9 | $52.6 | +55% |
| 2021 | $52.6 | $55.7 | +5.8% |
| 2022 | $55.7 | $49.7 | -11% |
| 2023 | $49.7 | $43.8 | -12% |
| 2024 | $43.8 | $44.0 | +0.5% |
| 2025 | $44.0 | $47.8 | +8.6% |
| 2026 YTD | $47.8 | $50.1 | +4.9% |
QGEN has finished higher in four of the last six years. It's up 4.9% so far in 2026.